Investigation of the difference among long acting insulin products in type 1 diabetes

Investigation of the difference among long acting insulin products in type 1 diabetes - Becoming Stable Glycemic Control with Basal Insulin Study(Best Basal Insulin Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009965

Enrollment

Registered

2013-02-05

Start date

2013-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes

Interventions

glargine , cross over degludec , cross over

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)insulin user- basal -bolus method (more than 1 year) 2) intrinsic insulin secretion completely exhasuted 3) be able to use self monitoring blood glucose

Exclusion criteria

Exclusion criteria: 1)other medication to affect glucose concentarion 2) within 6 nonths after new onset AMI 3) severe hypertension , liver dysfunction, renal dysfunction

Design outcomes

Primary

Measure	Time frame
satandard deviation(SD) and coefficiency of valiance (CV) in fasting blood glucose	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026